Skip to content
PeptideAI
Observationalskin

Haloxyl

A four-part complex for dark circles that chelates leaked iron, speeds bilirubin clearance and thickens the thin under-eye skin that lets the pigment show through.

Also known as Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7 + chrysin + N-hydroxysuccinimide, dark circle peptide complex, Haloxyl

Observational — Human data without randomisation. Suggestive, and easily confounded.

Sederma's own uncontrolled panels report dark-circle reduction in the 30-60% range over 8 weeks. There is no independent randomised trial, and the effect is confined to the haemoglobin-pigment subtype of dark circle.

How it works

Blue-brown under-eye circles are often haemoglobin breakdown products — iron and bilirubin left behind by leaked capillaries — showing through skin barely half a millimetre thick. Haloxyl attacks that on three fronts. N-hydroxysuccinimide chelates the accumulated iron and makes it soluble enough to be cleared. Chrysin, a flavonoid, upregulates UGT1A1, the enzyme that conjugates bilirubin for elimination. Palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 act as matrikines, increasing collagen and glycosaminoglycan content so the skin becomes less transparent and less inflamed. None of this touches circles caused by tear-trough anatomy or by genuine melanin hyperpigmentation.

Targets: Iron chelation, UGT1A1 / bilirubin conjugation, Collagen and glycosaminoglycan synthesis, Interleukin-6

Dosing

ProtocolDoseFrequencyRoute
Under-eye dark circle serumMorning and night, patted along the orbital rim and tear trough.—twice dailytopical
  • · The supplier's recommended use level is 2% of the finished formula. Water soluble; incorporate at up to 45 °C into emulsions or at room temperature into gels. Going above 2% does not improve results.

Cycling

Continuous daily use for at least 12 weeks before judging it.

Work out your exact syringe units →

Pharmacology

Half-life
Not applicable — this is a formulated complex, not a single molecule.
Onset
Supplier panels report measurable lightening by 4 weeks and larger effects by 8-12 weeks.
Routes
topical
Molecule
Blend of two palmitoylated peptides with a flavonoid and an iron chelator

Handling

Diluent
Supplied as a ready-to-use water-soluble liquid
Lyophilised
Not applicable.
Reconstituted
Cool, dark storage in the sealed supplier bottle; finished products should be preserved.
Light sensitive
Yes — keep it out of the light

Mixing

Not sold as a lyophilised powder; it is a formulated blend.

Side effects

  • commonYellow tint to the product— That is the chrysin; it is cosmetic, not degradation.
  • uncommonStinging on the thin periorbital skin

Do not use if

  • Dark circles that are actually tear-trough shadowing or melanin hyperpigmentation — this complex targets neither and you will waste twelve weeks finding that out.

Combining it

  • synergyeyeseryl — The conventional eye-contour pair: pigment plus puffiness.
  • redundantpalmitoyl-tripeptide-1 — Already one of Haloxyl's four actives.

What to monitor

  • · Photographs in flat, even, front-on lighting — angled light creates shadow that looks like pigment.

Legal status

Cosmetic ingredient blend approved worldwide under its component INCI names.

References

  • Sederma Haloxyl technical dossier (other)

Mechanism in depth

Haloxyl is the only product in this class built around a correct and specific pathophysiological model, which is why it deserves more respect than its evidence base alone would earn. Blue-brown infraorbital circles of the vascular subtype come from haemoglobin degradation products. Periorbital capillaries are fragile and the surrounding tissue has almost no structural support, so red cells extravasate. Haemoglobin released from those cells is broken down by haem oxygenase into biliverdin, which is reduced to bilirubin, while the iron is released separately. Bilirubin is yellow-orange, biliverdin is green, and iron-laden haemosiderin is brown — and all of that is sitting under skin about half a millimetre thick with essentially no dermal opacity to hide it. That is the blue-brown you see. Haloxyl attacks three points. N-hydroxysuccinimide chelates the free and haemosiderin iron, making it soluble and mobilisable. Chrysin induces UGT1A1, the enzyme that glucuronidates bilirubin and is the rate-limiting step in its clearance — the same enzyme that is deficient in Gilbert's syndrome. And the two matrikine peptides increase collagen and glycosaminoglycan content, thickening the skin so that whatever pigment remains is less visible. That is a coherent three-pronged attack on a specific, correctly identified problem. What is missing is any independent verification that it works in vivo, and any evidence at all for the other two dark-circle subtypes, which are tear-trough shadowing and true melanin hyperpigmentation. Those are common, especially in Fitzpatrick IV-VI, and Haloxyl does nothing for either.

What usually goes wrong

Subtype misdiagnosis, and it is the whole game. Pull the skin gently taut under your eye in a mirror: if the darkness disappears, it is shadowing from tear trough anatomy and no topical will fix it — that is a filler or a surgical problem. Stretch the skin and if the pigment stays, it is dermal melanin, and you need a pigment agent not an iron chelator. Haloxyl only works on the vascular-haemoglobin subtype, which typically looks blue-purple, is worse when you are tired or dehydrated, and shifts with head position. The second failure is time: the supplier's own panels ran eight weeks, and people abandon it at three. The third is the yellow tint — that is chrysin, it is normal, and it is not the product going off.

Pharmacokinetics

Crosses blood-brain barrier
no
Metabolism
Component-dependent. Chrysin is heavily glucuronidated — it is itself a UGT substrate as well as a UGT1A1 inducer, which is a slightly awkward pharmacological fact for the marketing. N-hydroxysuccinimide chelates iron and is cleared with it. The peptides are cleaved by esterases and peptidases.
Elimination
No meaningful systemic exposure at 2% of a topical eye product.

Receptor targets

  • Free and haemosiderin iron in periorbital tissue — N-hydroxysuccinimide is a known chelator; no affinity published for the periorbital application

    Solubilises and mobilises accumulated iron so it can be cleared.

  • UGT1A1 (UDP-glucuronosyltransferase 1A1) — Chrysin is a well-documented UGT1A1 inducer in cell systems

    Accelerates bilirubin glucuronidation and clearance, removing the yellow-brown component of the circle.

  • Dermal collagen and glycosaminoglycans (matrikine arm) — No receptor cloned

    Increases dermal opacity and thickness so residual pigment shows through less.

  • Interleukin-6 (palmitoyl tetrapeptide-7 arm) — Not published

    Reduces inflammatory signalling that contributes to capillary fragility.

What to expect, and when

Week 4: earliest measurable lightening in supplier panels. Week 8-12: the point at which the reported 30-60% reductions were measured. Anything before four weeks is lighting or hydration.

Stacking and comparisons

Eyeseryl is the standard partner and the logic is sound — one addresses pigment, the other addresses fluid, and most people's under-eye complaint is a mixture. Caffeine fits alongside both. If your circles have a melanin component, and they very often do in Fitzpatrick III and above, then the thing that actually works is a tyrosinase inhibitor plus rigorous sun protection, so decapeptide-12, tranexamic acid or azelaic acid belongs in the routine and Haloxyl alone will underperform. Vitamin K creams are frequently recommended for this indication and the evidence for them is worse than for Haloxyl. Do not layer a retinoid into the same step; periorbital skin does not tolerate it and the resulting irritation makes circles look worse.

The best-reasoned dark-circle topical on the market, which is a low bar. Against vitamin K creams, Haloxyl has a more specific mechanism and neither has independent randomised data. Against tranexamic acid or decapeptide-12, those target melanin and Haloxyl targets haemoglobin breakdown products — they are for different problems and the most common mistake is buying the wrong one. Against a tear-trough filler, no comparison for the shadowing subtype.

Rough cost

$15–$75/month. Supplied as a ready-to-use liquid at roughly $25-50 per 100 mL at a 2% use level, so DIY is cheap. Finished eye products containing it run $18-75 a month. Market observation, not a sourced pricing study.

Genuinely uncertain

  • No independent randomised trial exists. The 30-60% dark-circle reduction figures are uncontrolled Sederma panels.
  • The UGT1A1 induction by chrysin is documented in cell systems; whether it happens in periorbital skin at 2% topical exposure is unverified.
  • The iron chelation mechanism is chemically sound but has not been demonstrated to clear periorbital haemosiderin in vivo.
  • The relative contribution of the four components has never been separated.
  • No molecular weight is given because it is a formulated complex rather than a compound.

Papers